Increased levels of γ-glutamylamines in Huntington disease CSF

Journal of Neurochemistry

Volumn 106, Issue 1, 2008, Pages 37-44

  Jeitner, Thomas M ^a   Matson, Wayne R ^b   Folk, John E ^c   Blass, John P ^d,e   Cooper, Arthur J L ^d,e,f  

^a Red Anvil LLC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

glutamyl lysine; glutamylputrescine; glutamylspermidine; Bis glutamylputrescine; CSF; Huntington disease

Indexed keywords

2,4 DIAMINOGLUTARIC ACID; BRAIN PROTEIN; GAMMA GLUTAMYL EPSILON LYSINE; GAMMA GLUTAMYLPUTRESCINE; GAMMA GLUTAMYLSPERMIDINE; LYSINE DERIVATIVE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PUTRESCINE DERIVATIVE; SPERMIDINE DERIVATIVE;

ADULT; AGED; AMINATION; ARTICLE; ASSAY; BRAIN; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME ACTIVITY; ENZYME MODIFICATION; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINATION; BIOGENIC POLYAMINES; BIOLOGICAL MARKERS; BRAIN; FEMALE; GLUTAMINE; HUMANS; HUNTINGTON DISEASE; LYSINE; MALE; MIDDLE AGED; NEUROCHEMISTRY; PROTEIN PROCESSING, POST-TRANSLATIONAL; PUTRESCINE; SPERMIDINE; TRANSGLUTAMINASES; UP-REGULATION;

EID: 45449119171     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05350.x     Document Type: Article

References (43)

1. Cooper A. J. L., Jeitner T. M. Blass J. P. (2002) The role of transglutaminases in neurodegenerative diseases: overview. Neurochem. Int. 40, 1 5.
2. Cordella-Miele E., Miele L., Beninati S. Mukherjee A. B. (1993) Transglutaminase-catalyzed incorporation of polyamines into phospholipase A2. J. Biochem. 113, 164 173.
3. Danson J. W., Trawick M. L. Cooper A. J. L. (2002) Spectrophotometric assays for L-lysine α-oxidase and γ-glutamylamine cyclotransferase. Anal. Biochem. 303, 120 130.
4. Dedeoglu A., Kubilus J. K., Jeitner T. M. et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942 8950.
5. Fink M. L. Folk J. E. (1981) γ-Glutamylamine cyclotransferase. An enzyme involved in the catabolism of ε-(γ-glutamyl)lysine and other γ-glutamylamines. Mol. Cell. Biochem. 38, 59 67.
6. Fink M. L., Chung S. I. Folk J. E. (1980) γ-Glutamylamine cyclotransferase: specificity toward ε-(L-γ-glutamyl)-L-lysine and related compounds. Proc. Natl Acad. Sci. USA 77, 4564 4568.
7. 4-bis(γ-glutamyl)putrescine. Methods Enzymol. 94, 451 457.
8. Folk J. E. Finlayson J. S. (1977) The ε-(γ-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv. Protein Chem. 31, 1 133.
9. Folk J. E., Park M. H., Chung S. I., Schrode J., Lester E. P. Cooper H. L. (1980) Polyamines as physiological substrates for transglutaminases. J. Biol. Chem. 255, 3695 3700.
10. Fox J. H., Barber D. S., Singh B. et al. (2004) Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91, 413 422.
11. Goodnow R. Jr, Konno K., Niwa M., Kallimopoulos T., Bukownik R., Lenares D. Nakanishi K. (1990) Synthesis of glutamate receptor antagonist philanthotoxin-433 (PhTx-433) and its analogs. Tetrahedron 46, 3267 3289.
12. Griffin M., Casadio R. Bergamini C. M. (2002) Transglutaminases: nature's biological glues. Biochem. J. 368, 377 396.
13. Harsfalvi J., Tarcsa E., Udvardy M., Zajka G., Szarvas T. Fésüs L. (1992) Presence and possible origin of ε(γ- glutamyl)lysine isodipeptide in human plasma. Thromb. Hemost. 67, 60 62.
14. Jeitner T. M., Fuchsbauer H. L., Blass J. P. Cooper A. J. L. (2001a) A sensitive fluorometric assay for tissue transglutaminase. Anal. Biochem. 292, 198 206.
15. ε-(γ-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J. Neurochem. 79, 1109 1112.
16. Jeitner T. M., Delikatny E. J., Ahlqvist J., Capper H. R. Cooper A. J. L. (2005) Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. 69, 961 970.
17. Karpuj M. V., Garren H., Slunt H., Price D. L., Gusella J., Becher M. W. Steinman L. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl Acad. Sci. USA 96, 7388 7393.
18. Karpuj M. V., Becher M. W., Springer J. E., Chabas D., Youssef S., Pedotti R., Mitchell D. Steinman L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143 149.
19. Kim S. Y., Grant P., Lee J. H., Pant H. C. Steinert P. M. (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J. Biol. Chem. 274, 30715 30721.
20. Kim S. Y., Jeitner T. M. Steinert P. M. (2002) Transglutaminases in disease. Neurochem. Int. 40, 85 103.
21. Krapcho A. P. Kuell C. S. (1990) Mono-protected diamines. N-tert-Butyloxycarbonyl-α,ω-alkanediamines from α,ω- alkanediamines. Synthetic Commun. 20, 2559 2564.
22. Lesort M., Chun W., Johnson G. V. W. Ferrante R. J. (1999) Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 73, 2018 2027.
23. Lorand L. Graham R. M. (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140 156.
24. Lorand L., Parameswaran K. N., Stenberg P., Tong Y. S., Velasco P. T., Jonsson N. A., Mikiver L. Moses P. (1979) Specificity of guinea pig liver transglutaminase for amine substrates. Biochemistry 18, 1756 1765.
25. Martin N. A., Romito G., Pepe I., De Vivo G., Merola M. R., Limatola A. Gentile V. (2006) Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease: from basic biochemistry to clinic. Curr. Med. Chem. 13, 1895 1902.
26. Mastroberardino P. G., Iannicola C., Nardacci R. et al. (2002) 'Tissue' transglutaminase ablation reduces neuronal cell death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 9, 873 880.
27. Masuda M., Betancourt L., Matsuzawa T., Kashimoto T., Takao T., Shimonishi Y. Horiguchi Y. (2000) Activation of Rho through a cross-link with polyamines catalyzed by Bordetella dermonecrotizing toxin. EMBO J. 19, 521 530.
28. Mehta A., Jaouhari R., Benson T. J. Douglas K. T. (1992) Improved efficiency and selectivity in peptide synthesis: use of a triethylsilane as a carbocation scavenger in deprotection of t-butyl esters and t-butoxycarbonyl- protected sites. Tetrahedron Lett. 33, 5441 5444.
29. Molberg O., McAdam S. N., Korner R. et al. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4, 713 717.
30. Muma N. A. (2007) Transglutaminase is linked to neurodegenerative diseases. J. Neuropathol. Expt. Med. 66, 258 263.
31. Nakajima T., Kakimoto Y., Tsuji M. Konoshsi H. (1976) Occurrence and formation of γ-glutamylputrescine in mammalian brain. J. Neurochem. 26, 115 118.
32. Nemes Z., Marekov L. N., Fésüs L. Steinert P. M. (1999) A novel function for transglutaminase 1: attachment of long-chain ω-hydroxyceramides to involucrin by ester bond formation. Proc. Natl Acad. Sci. USA 96, 8402 8407.
33. ε(γ-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia. Neurobiol. Aging 22, 403 406.
34. Nemes Z., Devreese B., Steinert P. M., van Beeumen J. Fésüs L. (2004) Cross linking of ubiquitin, HSP27, parkin, and α-synuclein by γ-glutamyl-ε-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J. 18, 1135 1137.
35. Parameswaran K. N., Cheng X.-F., Chen E. C., Velasco P. T., Wilson J. H. Lorand L. (1997) Hydrolysis of γ:ε isopeptides by cytosolic transglutaminases and by coagulation factor XIIIa. J. Biol. Chem. 272, 10311 10317.
36. Poduslo J. F. Curran G. L. (1996) Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J. Neurochem. 66, 1599 1609.
37. Ruan Q. Johnson G. V. W. (2007) Transglutaminases in neurodegenerative diseases. Front. Biosci. 12, 891 904.
38. Sárvári M., Fésüs L. Nemes Z. (2002) Transglutaminase-mediated crosslinking of neural proteins in Alzheimer's disease and other primary dementias. Drug Develop. Res. 56, 458 472.
39. Tremblay M. E., Saint-Pierre M., Bourhis E., Lévesque D., Rouillard C. Cicchetti F. (2006) Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol. Aging 27, 862 870.
40. Van Raamsdonk J. M., Pearson J., Bailey C. D. C., Rogers D. A., Johnson G. V. W., Hayden M. R. Leavitt B. R. (2005) Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J. Neurochem. 95, 210 220.
41. Vivó M., de Vera N., Cortés R., Mengod G., Camón L. Martínez E. (2001) Polyamines in the basal ganglia of human brain. Influence of aging and degenerative movement disorders. Neurosci. Lett. 304, 107 111.
42. Wang X., Sarkar A., Cicchetti F., Yu M., Zhu A., Jokivarsi K., Saint-Pierre M. Brownell A. L. (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J. Neurol. Sci. 231, 57 66.
43. Zainelli G. M., Ross C. A., Troncoso J. C. Muma N. A. (2003) Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J. Neuropathol. Expt. Neurol. 62, 14 24.